Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Nat Med · 2026 · PMC13099643 · PMID 41912809

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

a positive trendP = 0.073so close (0.05 < p ≤ 0.1)

Maximal decrease in NR4A family expression after treatment was associated with a positive trend toward improved PFS (hazard ratio = 0.49 (95% CI: 0.22–1.08); P = 0.073) and was significantly associated with improved OS (hazard ratio = 0.24 (95% CI: 0.08–0.67); P = 0.0035) (Fig. 3e,f ).

also in 5,550 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.